Suono Bio is based on MIT research and is aiming to use low-frequency ultrasound to bring therapeutic compounds to target cells with greater efficiency.
Suono Bio, a US-based drug delivery technology developer based on Massachusetts Institute of Technology (MIT) research, has received an undisclosed sum of funding from diversified imaging and medical group Fujifilm.
Founded in 2017, Suono Bio is developing medications for inflammatory-mediated diseases that will exploit its drug delivery technology to ensure compounds reach target cells quickly and efficiently.
Suono Bio’s approach uses low-frequency ultrasound to help administer small molecules, biologics and nucleic acids into the body, potentially facilitating the creation of drugs for previously untreatable diseases.
The technology has been tested in pre-clinical studies targeting a range of conditions with therapeutic candidates, including some made of genetic material. Fujifilm’s investment will be used to push Suono Bio’s work further into development.
Suono Bio previously received an unspecified amount of funding from the Engine fund, an MIT-backed vehicle linked to the university’s Engine incubator.
Polaris Partners and MedTech Venture Partners have also backed Suono Bio previously, though details could not be ascertained.
Suono Bio was co-founded by Robert Langer, institute professor at the Department of Chemical Engineering, and Giovanni Traverso, assistant professor at Harvard Medical School and a gastroenterologist at Brigham and Women’s Hospital.
Carl Schoellhammer, a former quinquennial postdoctoral fellow in Langer’s laboratory, and Amy Schulman, partner at Polaris Partners, also helped start the company.
